Comparative Pharmacology
Head-to-head clinical analysis: HUMATIN versus TOBRAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMATIN versus TOBRAMYCIN SULFATE.
HUMATIN vs TOBRAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
Adults: Tobramycin 3-5 mg/kg/day IV divided every 8 hours, or 5-7 mg/kg/day IV once daily. For inhalation: 300 mg nebulized twice daily.
None Documented
None Documented
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 24-100 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Primarily renal (glomerular filtration) with 90-95% excreted unchanged in urine within 24 hours; biliary/fecal <1%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic